Payment overview · 2025
General Payments
$856.97
30 reported records · 14 companies
Healthcare provider profile · identity verified
Steven Glenn Clark, M.D
Allopathic & Osteopathic Physicians|Internal Medicine · CLEVELAND, MS · NPI 1053408476
Verified facts
What the public records show
CMS Open Payments records show Steven Glenn Clark, M.D received $856.97 in general payments during 2025 across 30 reported records.
AstraZeneca Pharmaceuticals LP accounted for 23.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Jardiance, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 293 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 403 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 648 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 648 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 185 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 303 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 909 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $204.34 | 23.8% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $158.07 | 18.4% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $84.38 | 9.8% | 4 | 2025 |
| Alpha Cognition USA, Inc. | Unresolved — no canonical attribution shown | $67.69 | 7.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $52.03 | 6.1% | 3 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $44.59 | 5.2% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $40.18 | 4.7% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $38.37 | 4.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $36.93 | 4.3% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $34.68 | 4.0% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $33.78 | 3.9% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $27.91 | 3.3% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $20.42 | 2.4% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $13.60 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $856.97 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $168.16 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $144.52 | 2 | 2025 |
Source payment records
|
|||||
| Zunveyl Normalized: zunveyl |
Drug | Alpha Cognition USA, Inc. | $67.69 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $52.03 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $52.03 | 3 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $44.59 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $40.18 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $38.37 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $37.98 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $37.98 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $36.93 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $36.93 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $33.78 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $27.91 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $22.62 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $20.42 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.99 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $18.99 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.99 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $13.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 25 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 648 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 185 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 303 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
293 | 81 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
129 | 33 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
138 | 22 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
403 | 83 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
648 | 121 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
648 | 121 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
185 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
137 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
303 | 65 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
25 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
909 | 160 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 1932 | 465 |
| Potassium Chloride | Potassium Chloride | 1699 | 353 |
| Pantoprazole Sodium | Pantoprazole Sodium | 1461 | 307 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1378 | 263 |
| Furosemide | Furosemide | 1375 | 300 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1370 | 309 |
| Famotidine | Famotidine | 1319 | 259 |
| Metoprolol Succinate | Metoprolol Succinate | 1131 | 288 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 1037 | 273 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 984 | 263 |
| Gabapentin | Gabapentin | 913 | 173 |
| Eliquis | Apixaban | 909 | 160 |
| Losartan Potassium | Losartan Potassium | 744 | 170 |
| Clopidogrel | Clopidogrel Bisulfate | 653 | 151 |
| Jardiance | Empagliflozin | 648 | 121 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 625 | 129 |
| Metformin Hcl Er | Metformin Hcl | 618 | 152 |
| Donepezil Hcl | Donepezil Hcl | 538 | 111 |
| Hydralazine Hcl | Hydralazine Hcl | 523 | 100 |
| Escitalopram Oxalate | Escitalopram Oxalate | 522 | 113 |
| Spironolactone | Spironolactone | 509 | 142 |
| Carvedilol | Carvedilol | 474 | 99 |
| Mirtazapine | Mirtazapine | 469 | 94 |
| Prednisone | Prednisone | 465 | 260 |
| Allopurinol | Allopurinol | 451 | 78 |
| Tamsulosin Hcl | Tamsulosin Hcl | 433 | 109 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 426 | 326 |
| Quetiapine Fumarate | Quetiapine Fumarate | 422 | 51 |
| Omeprazole | Omeprazole | 409 | 99 |
| Farxiga | Dapagliflozin Propanediol | 403 | 83 |
| Metformin Hcl | Metformin Hcl | 377 | 79 |
| Metoprolol Tartrate | Metoprolol Tartrate | 374 | 71 |
| Diclofenac Sodium | Diclofenac Sodium | 370 | 149 |
| Montelukast Sodium | Montelukast Sodium | 345 | 85 |
| Duloxetine Hcl | Duloxetine Hcl | 341 | 74 |
| Alprazolam | Alprazolam | 323 | 86 |
| Simvastatin | Simvastatin | 308 | 75 |
| Ozempic | Semaglutide | 303 | 65 |
| Nifedipine Er | Nifedipine | 298 | 66 |
| Pravastatin Sodium | Pravastatin Sodium | 295 | 57 |
| Linzess | Linaclotide | 293 | 81 |
| Tresiba Flextouch U-200 | Insulin Degludec | 285 | 67 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 279 | 72 |
| Levetiracetam | Levetiracetam | 278 | 36 |
| Amiodarone Hcl | Amiodarone Hcl | 270 | 61 |
| Clonazepam | Clonazepam | 257 | 53 |
| Clonidine | Clonidine | 255 | 55 |
| Doxycycline Hyclate | Doxycycline Hyclate | 230 | 173 |
| Buspirone Hcl | Buspirone Hcl | 226 | 57 |
| Lisinopril | Lisinopril | 226 | 43 |
| Sertraline Hcl | Sertraline Hcl | 213 | 37 |
| Meloxicam | Meloxicam | 210 | 63 |
| Colchicine | Colchicine | 206 | 56 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 205 | 58 |
| Irbesartan | Irbesartan | 196 | 49 |
| Azithromycin | Azithromycin | 195 | 167 |
| Tizanidine Hcl | Tizanidine Hcl | 195 | 52 |
| Tramadol Hcl | Tramadol Hcl | 194 | 63 |
| Bupropion Xl | Bupropion Hcl | 186 | 41 |
| Mounjaro | Tirzepatide | 185 | 33 |
| Trazodone Hcl | Trazodone Hcl | 185 | 41 |
| Desloratadine | Desloratadine | 184 | 74 |
| Memantine Hcl | Memantine Hcl | 184 | 31 |
| Fluconazole | Fluconazole | 182 | 109 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 181 | 48 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 180 | 57 |
| Meclizine Hcl | Meclizine Hcl | 178 | 58 |
| Midodrine Hcl | Midodrine Hcl | 175 | 37 |
| Zolpidem Tartrate | Zolpidem Tartrate | 174 | 34 |
| Cefdinir | Cefdinir | 170 | 139 |
| Xarelto | Rivaroxaban | 169 | 24 |
| Pregabalin | Pregabalin | 167 | 44 |
| Ropinirole Hcl | Ropinirole Hcl | 160 | 36 |
| Trimethoprim | Trimethoprim | 159 | 31 |
| Entresto | Sacubitril/Valsartan | 158 | 36 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 158 | 37 |
| Celecoxib | Celecoxib | 155 | 53 |
| Hydrochlorothiazide | Hydrochlorothiazide | 153 | 42 |
| Estradiol | Estradiol | 150 | 36 |
| Warfarin Sodium | Warfarin Sodium | 143 | 21 |
| Cilostazol | Cilostazol | 140 | 23 |
| Fenofibrate | Fenofibrate Nanocrystallized | 140 | 24 |
| Megestrol Acetate | Megestrol Acetate | 139 | 58 |
| Myrbetriq | Mirabegron | 138 | 22 |
| Trulicity | Dulaglutide | 137 | 20 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 135 | 28 |
| Ranolazine Er | Ranolazine | 134 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 131 | 43 |
| Colesevelam Hcl | Colesevelam Hcl | 131 | 37 |
| Verapamil Er | Verapamil Hcl | 131 | 31 |
| Synthroid | Levothyroxine Sodium | 129 | 33 |
| Sucralfate | Sucralfate | 128 | 31 |
| Atenolol | Atenolol | 127 | 35 |
| Amitriptyline Hcl | Amitriptyline Hcl | 126 | 26 |
| Ezetimibe | Ezetimibe | 124 | 38 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 123 | 37 |
| Glimepiride | Glimepiride | 118 | 34 |
| Promethazine Hcl | Promethazine Hcl | 115 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 113 | 18 |
| Ondansetron Odt | Ondansetron | 112 | 57 |
| Eszopiclone | Eszopiclone | 106 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 105 | 34 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 104 | 89 |
| Lactulose | Lactulose | 102 | 23 |
| Baclofen | Baclofen | 100 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 100 | 56 |
| Clonidine Hcl | Clonidine Hcl | 99 | 25 |
| Aripiprazole | Aripiprazole | 95 | 12 |
| Divalproex Sodium | Divalproex Sodium | 94 | 13 |
| Finasteride | Finasteride | 93 | 23 |
| Terbinafine Hcl | Terbinafine Hcl | 93 | 36 |
| Fluoxetine Hcl | Fluoxetine Hcl | 92 | 16 |
| Aptiom | Eslicarbazepine Acetate | 91 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 90 | 44 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 90 | 56 |
| Lovastatin | Lovastatin | 87 | 13 |
| Alendronate Sodium | Alendronate Sodium | 86 | 15 |
| Doxepin Hcl | Doxepin Hcl | 86 | 15 |
| Latanoprost | Latanoprost | 85 | 21 |
| Methocarbamol | Methocarbamol | 85 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 84 | 46 |
| Oxybutynin Chloride | Oxybutynin Chloride | 82 | 16 |
| Novolog Flexpen | Insulin Aspart | 80 | 26 |
| Risperidone | Risperidone | 79 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 78 | 11 |
| Azelastine Hcl | Azelastine Hcl | 76 | 46 |
| Methylprednisolone | Methylprednisolone | 76 | 71 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 74 | 23 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 73 | 22 |
| Doxazosin Mesylate | Doxazosin Mesylate | 72 | 20 |
| Valacyclovir | Valacyclovir Hcl | 72 | 40 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 71 | 18 |
| Mupirocin | Mupirocin | 71 | 52 |
| Dutasteride | Dutasteride | 69 | 16 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 68 | suppressed |
| Januvia | Sitagliptin Phosphate | 67 | 15 |
| Levofloxacin | Levofloxacin | 67 | 59 |
| Solifenacin Succinate | Solifenacin Succinate | 66 | 18 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 66 | 57 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 65 | 15 |
| Minoxidil | Minoxidil | 62 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 59 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 59 | 14 |
| Tradjenta | Linagliptin | 59 | suppressed |
| Valsartan | Valsartan | 58 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 55 | 26 |
| Pioglitazone Hcl | Pioglitazone Hcl | 54 | 14 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 53 | suppressed |
| Novolog | Insulin Aspart | 53 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 53 | suppressed |
| Cephalexin | Cephalexin | 52 | 33 |
| Sotalol | Sotalol Hcl | 52 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 51 | 14 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 51 | 18 |
| Haloperidol | Haloperidol | 51 | 11 |
| Santyl | Collagenase Clostridium Hist. | 51 | 16 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 50 | 23 |
| Diazepam | Diazepam | 49 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 49 | 22 |
| Fenofibrate | Fenofibrate | 48 | 16 |
| Lansoprazole | Lansoprazole | 48 | 13 |
| Insulin Lispro | Insulin Lispro | 47 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 47 | 11 |
| Albuterol Sulfate | Albuterol Sulfate | 45 | 23 |
| Nebivolol Hcl | Nebivolol Hcl | 44 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 43 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 43 | 21 |
| Digoxin | Digoxin | 43 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 43 | 13 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 42 | 12 |
| Benazepril Hcl | Benazepril Hcl | 41 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 40 | 12 |
| Mometasone Furoate | Mometasone Furoate | 40 | 36 |
| Flecainide Acetate | Flecainide Acetate | 39 | suppressed |
| Carbamazepine | Carbamazepine | 38 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 38 | suppressed |
| Insulin Aspart | Insulin Aspart | 38 | 16 |
| Bumetanide | Bumetanide | 37 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 37 | 19 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 37 | 19 |
| Bethanechol Chloride | Bethanechol Chloride | 36 | suppressed |
| Fentanyl | Fentanyl | 36 | 13 |
| Methotrexate | Methotrexate Sodium | 36 | suppressed |
| Metronidazole | Metronidazole | 35 | 27 |
| Benztropine Mesylate | Benztropine Mesylate | 34 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 34 | suppressed |
| Glucagon Emergency Kit | Glucagon | 34 | 17 |
| Methimazole | Methimazole | 33 | suppressed |
| Nitroglycerin | Nitroglycerin | 33 | 23 |
| Primidone | Primidone | 33 | 11 |
| Linezolid | Linezolid | 31 | 25 |
| Metoclopramide Hcl | Metoclopramide Hcl | 31 | suppressed |
| Torsemide | Torsemide | 31 | suppressed |
| Azathioprine | Azathioprine | 30 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 30 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 30 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 30 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 30 | suppressed |
| Topiramate | Topiramate | 30 | suppressed |
| Ertapenem | Ertapenem Sodium | 29 | 20 |
| Folic Acid | Folic Acid | 29 | suppressed |
| Ibuprofen | Ibuprofen | 29 | 11 |
| Olanzapine | Olanzapine | 29 | suppressed |
| Phenobarbital | Phenobarbital | 29 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 28 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 28 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 28 | suppressed |
| Chlorthalidone | Chlorthalidone | 27 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 27 | 19 |
| Diltiazem Hcl | Diltiazem Hcl | 27 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 27 | 12 |
| Labetalol Hcl | Labetalol Hcl | 27 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 27 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 27 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 27 | 13 |
| Glipizide | Glipizide | 26 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 25 | 25 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 25 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 25 | suppressed |
| Levemir Flexpen | Insulin Detemir | 25 | 11 |
| Lubiprostone | Lubiprostone | 25 | suppressed |
| Metolazone | Metolazone | 25 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Gemfibrozil | Gemfibrozil | 24 | suppressed |
| Klor-Con M20 | Potassium Chloride | 24 | suppressed |
| Nystatin | Nystatin | 24 | 19 |
| Humalog | Insulin Lispro | 23 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 23 | suppressed |
| Telmisartan | Telmisartan | 23 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 22 | suppressed |
| Budesonide | Budesonide | 22 | 11 |
| Carbamazepine Er | Carbamazepine | 22 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 22 | 14 |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Movantik | Naloxegol Oxalate | 22 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 22 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Levemir | Insulin Detemir | 21 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 21 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 21 | 19 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Clotrimazole | Clotrimazole | 20 | 20 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 20 | suppressed |
| Fluocinonide | Fluocinonide | 20 | 12 |
| Raloxifene Hcl | Raloxifene Hcl | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 20 | suppressed |
| Temazepam | Temazepam | 20 | suppressed |
| Lorazepam | Lorazepam | 19 | suppressed |
| Amantadine | Amantadine Hcl | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 18 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Brilinta | Ticagrelor | 17 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 17 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 17 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 17 | suppressed |
| Phenytoin | Phenytoin | 17 | suppressed |
| Repatha Sureclick | Evolocumab | 17 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 17 | 14 |
| Theophylline Er | Theophylline Anhydrous | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Anastrozole | Anastrozole | 16 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 16 | 14 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Gemtesa | Vibegron | 16 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 16 | suppressed |
| Niacin Er | Niacin | 16 | suppressed |
| Silodosin | Silodosin | 16 | suppressed |
| Sod Sulf-Potass Sulf-Mag Sulf | Sodium, Potassium,mag Sulfates | 16 | 14 |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 15 | suppressed |
| Effer-K | Potassium Bicarbonate/Cit Ac | 15 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Progesterone | Progesterone, Micronized | 15 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 15 | suppressed |
| Teriflunomide | Teriflunomide | 15 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Dexamethasone | Dexamethasone | 14 | suppressed |
| Entacapone | Entacapone | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Insulin Degludec Pen (U-200) | Insulin Degludec | 14 | 11 |
| Kerendia | Finerenone | 14 | suppressed |
| Lacosamide | Lacosamide | 14 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 14 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 14 | suppressed |
| Timolol Maleate | Timolol Maleate | 14 | suppressed |
| Fluorouracil | Fluorouracil | 13 | 12 |
| Privigen | Immun Glob G(Igg)/Pro/Iga 0-50 | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Zaleplon | Zaleplon | 13 | suppressed |
| Zonisamide | Zonisamide | 13 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 12 | 12 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 12 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 12 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Indapamide | Indapamide | 11 | suppressed |
| Misoprostol | Misoprostol | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $856.97 · 30 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, AUSTEDO XR, COMIRNATY, Dexcom G6 Transmitter, IBSRELA, JARDIANCE, KISUNLA, Leqembi, MOUNJARO, NEXLETOL, Ozempic, PREVNAR 20, QULIPTA, REXULTI, Rybelsus, UBRELVY, Veozah, ZEPBOUND, Zunveyl | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error